In challenging one portion of the history presented in my article, Healy et al. argue that Louis Lasagna was a ‘classical liberal’ who sought only to increase the scientific stature of the physician–patient encounter. They advance this interpretation to encourage science and technology studies scholars to heed Lasagna’s ideas about how to organize the medical marketplace. I argue that Healy et al. mischaracterize Lasagna’s ideas. I conclude with an example of these ideas being put into practice, Lasagna’s efforts on behalf of Wyeth in the approval and marketing of Redux and Fen-Phen.
CarpenterD (2010) Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton, NJ: Princeton University Press.
2.
ElliottC (2004) Pharma goes to the laundry. Hastings Center Report34(5): 18–23.
3.
FriedmanM (1962) Capitalism and Freedom. Chicago, IL: The University of Chicago Press.
4.
GreeneJPodolskyS (2009) Keeping modern in medicine: Pharmaceutical promotion and physician education in postwar America. Bulletin of the History of Medicine83(2): 331–378.
5.
HealyD (2012) Pharmageddon. Berkeley, CA: University of California Press.
6.
HealyDManginDApplbaumK (2014) The shipwreck of the singular. Social Studies of Science44(4): 518–523.
7.
HiltsP (2003) Protecting America’s Health. New York: Knopf.
8.
KauffmanMJulienA (2000) Scientists helped industry to push diet drug. Hartford Courant, 10April, A1.
9.
KnoxRRosenbergR (1997) Major questions not yet answered in diet pill debacle. The Boston Globe, 22September, A1.
10.
LasagnaL (1974) Bureaucratic controls will stifle both industry and intelligent medical practice. In: IngelfingerFEbertRFinlandMRelmanA (eds) Controversy in Internal Medicine II. Philadelphia, PA: WB Saunders, pp. 74–80.
11.
LasagnaL (1976) Drug discovery and introduction: Regulation and overregulation. Clinical Pharmacology & Therapeutics20(5): 507–511.
12.
LasagnaL (1998) Rx: A heftier share for prescription drugs. Boston Sunday Globe, 29November, D2.
13.
MarksHM (2000) The Progress of Experiment. Cambridge: Cambridge University Press.
14.
Nik-KhahE (2011) George Stigler, the Graduate School of Business, and the pillars of the Chicago School. In: Van HornRMirowskiPStaplefordT (eds) Building Chicago Economics. New York: Cambridge University Press, pp. 116–147.
15.
Nik-KhahE (2014) Neoliberal pharmaceutical science and the Chicago School of Economics. Social Studies of Science44(4): 489–517.
